

Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

Sook-Bin Woo, DMD; John W. Hellstein, DDS, MS; and John R. Kalmar, DMD, PhD

Osteonecrosis of the jaws is a recently described adverse side effect of bisphosphonate therapy. Patients with multiple myeloma and metastatic carcinoma to the skeleton who are receiving intravenous, nitrogen-containing bisphosphonates are at greatest risk for osteonecrosis of the jaws; these patients represent 94% of published cases. The mandible is more commonly affected than the maxilla (2:1 ratio), and 60% of cases are preceded by a dental surgical procedure. Oversuppression of bone turnover is probably the primary mechanism for the development of this condition, although there may be contributing comorbid factors. All sites of potential jaw infection should be eliminated before bisphospho-

nate therapy is initiated in these patients to reduce the necessity of subsequent dentoalveolar surgery. Conservative débridement of necrotic bone, pain control, infection management, use of antimicrobial oral rinses, and withdrawal of bisphosphonates are preferable to aggressive surgical measures for treating this condition. The degree of risk for osteonecrosis in patients taking oral bisphosphonates, such as alendronate, for osteoporosis is uncertain and warrants careful monitoring.

Ann Intern Med. 2006;144:753-761.

www.annals.org

For author affiliations, see end of text.

Bisphosphonates are used to treat osteoporosis, Paget disease of bone and other metabolic bone diseases, multiple myeloma, and skeletal events associated with metastatic neoplasms. Their primary mechanism of action is inhibition of osteoclastic resorption of bone. Within the past 2 years, an increasing body of literature has suggested that bisphosphonate use, especially intravenous preparations, may be associated with osteonecrosis of the jaws. We briefly review the action of bisphosphonates, outline the clinical manifestations of bisphosphonate-associated osteonecrosis of the jaws, summarize current treatment strategies, discuss possible mechanisms of etiopathogenesis, and suggest avenues of research.

METHODS

We performed MEDLINE and PubMed searches of English- and foreign-language literature (1966 to 31 January 2006) using the following Medical Subject Headings (MeSH) and terms: *osteonecrosis*, *avascular necrosis*, *phosphorous necrosis*, *bisphosphonates*, and *diphosphonates*. We then crossed the same terms with the terms *jaw diseases*, *myeloma*, *breast cancer*, and *metastatic cancer*. Other references were obtained from citations from retrieved articles. Similar terms were used to search abstracts from meetings of the American Society of Clinical Oncology.

We specifically reviewed all case reports and case series of patients with bisphosphonate-associated osteonecrosis of the jaws. We included any report that provided acceptable documentation of disease and use of bisphosphonates, regardless of whether it included information on the sex of patients, the site of the lesions, and the bisphosphonate used. Several authors published more than 1 paper describing patients with osteonecrosis. Through direct communication with these authors, we confirmed that some of the same patients were included in multiple reports. When this occurred, we used and cited data only from the larger, more recent publication.

No funding was received for this study.

ACTIONS OF BISPHOSPHONATES

Bisphosphonates are powerful inhibitors of osteoclastic activity. They are analogues of inorganic pyrophosphates with low intestinal absorption, are excreted through the kidneys without metabolic alteration, and have a high affinity for hydroxyapatite crystals (1, 2). Because they are incorporated into the skeleton without being degraded, they are remarkably persistent drugs; the estimated half-life for alendronate is up to 12 years (3). Alendronate, risedronate, pamidronate, zoledronic acid, and ibandronate, which are called aminobisphosphonates, have much higher potency because they contain nitrogen in a side chain (Table 1).

The nonaminobisphosphonates are metabolized by osteoclasts to inactive nonhydrolyzable adenosine triphosphate analogues that are directly cytotoxic to the cell and induce apoptosis (1, 2). The newer aminobisphosphonates have 2 actions (4): induction of another adenosine triphosphate analogue that induces apoptosis, and inhibition of farnesyl diphosphonate synthase, which is part of the mevalonate pathway of cholesterol synthesis. Such inhibition results in dysregulation of intracellular transport, cytoskeletal organization, and cell proliferation, leading to inhibition of osteoclast function. In addition, aminobisphosphonates reduce recruitment of osteoclasts and induce osteoblasts to produce an osteoclast-inhibiting factor (5, 6).

Aminobisphosphonates exert several antitumor effects, including induction of tumor cell apoptosis, inhibition of tumor cell adhesion to the extracellular matrix, and inhibition of tumor invasion (4, 7). Bisphosphonates also have

See also:

Print

Key Summary Points 758

Web-Only

CME quiz

Conversion of figures and tables into slides

antiangiogenesis properties (8, 9) and can activate $\gamma\delta$ T cells (10, 11). The use of bisphosphonates in patients with multiple myeloma and metastatic cancer to the bones, such as breast, prostate, lung, and renal cell carcinomas, has resulted in a statistically significant reduction in skeletal complications, including pathologic fractures, spinal cord compression, hypercalcemia of malignant disease, and the need for subsequent radiotherapy or surgery to bone (12–14). Intravenous bisphosphonates have improved bioavailability and do not produce gastrointestinal side effects, resulting in better patient adherence. They have become standard therapy in the management of patients with multiple myeloma and metastatic cancer.

POTENTIAL ADVERSE EFFECTS OF BISPHOSPHONATE ACTIONS

In normal bone homeostasis, osteoclastic resorption is tightly linked to osteoblastic bone deposition and both functions are essential for repair of physiologic microdamage. Prolonged use of bisphosphonates may suppress bone turnover to the point that such microdamage persists and accumulates (15). The result is hypodynamic bone with decreased biomechanical competence. Although osteoblastic function is also reduced during bisphosphonate therapy, continued mineralization yields a hard, brittle bone with an osteopetrotic appearance and an increased risk for fracture (16–18). Thus, some experts caution that the benefits of prolonged use of bisphosphonates must be carefully weighed against the potential negative effects of oversuppression of bone metabolism (1, 19, 20). Other experts argue that although long-term use of bisphosphonates may

retard fracture healing or slow callus remodeling, it may not affect bone mineralization or mechanical properties (21, 22).

ORAL COMPLICATIONS OF BISPHOSPHONATE THERAPY

Although oral bisphosphonates may cause oral mucosal lesions (purportedly arising from direct contact injury) (23, 24), we focus our review on bisphosphonate-associated osteonecrosis of the jaw. Table 2 summarizes 368 reported cases of bisphosphonate-associated osteonecrosis of the jaw (25–54). Reported cases manifested as exposure of portions of the bone of the mandible only (65%), maxilla only (26%), or both (9%). Approximately one third of lesions were painless (27), and there was a slight female predilection in a ratio of 3:2 among all reported cases. Multifocal or bilateral involvement was slightly more common in the maxilla than in the mandible (31% vs. 23%). Most lesions were on the posterior lingual mandible near the mylohyoid ridge. Of importance, 60% of cases occurred after a tooth extraction or other dentoalveolar surgery and the remaining cases occurred spontaneously. The latter cases often involved patients wearing dentures, a possible source of local trauma. Marx and colleagues (27) reported that 39% of cases that occurred spontaneously were located on bony exostoses that were easily traumatized. There is 1 case report of dental implant failure associated with bisphosphonate use (55).

Most patients (94%) were treated with intravenous bisphosphonates (primarily pamidronate and zoledronic acid), and most patients (85%) had multiple myeloma or metastatic breast cancer (Table 3). The remaining patients

Table 1. Bisphosphonate Formulations*

| Generic Name | Brand Name | Manufacturer and Location | Dosage Forms | Nitrogen-Containing | FDA Approval Date |
|--|----------------------|--|---|---------------------|--|
| Etidronate disodium | Didronel | Procter & Gamble Pharmaceuticals, Cincinnati, Ohio | 200- and 400-mg tablets | No | 1 September 1977 |
| Clodronate disodium | Bonefos (Canada) | Schering AG, Berlin, Germany | 400- and 800-mg tablets; 60 mg/mL ampulet | No | Not approved |
| Tiludronate disodium | Skelid | Sanofi-Synthelabo Inc., New York, New York | 200-mg tablet | No; sulfur moiety | 7 March 1997 |
| Alendronate sodium | Fosamax | Merck & Co. Inc., Whitehouse Station, New Jersey | 5-, 10-, 35-, 40-, and 70-mg tablets; 70 mg/75 mL oral solution | Yes | 29 September 1995 |
| Alendronate sodium plus vitamin D ₃ | Fosamax plus D | Merck & Co. Inc., Whitehouse Station, New Jersey | 70-mg and 2800-U cholecalciferol tablet | Yes | 7 April 2005 |
| Pamidronate disodium | Aredia | Novartis Pharmaceuticals, East Hanover, New Jersey | 30-, 60-, and 90-mg vial† | Yes | 31 October 1991 |
| Risedronate sodium | Actonel | Procter & Gamble Pharmaceuticals, Cincinnati, Ohio | 5-, 30-, and 35-mg tablets | Yes | 27 March 1998 |
| Risedronate sodium plus calcium | Actonel with calcium | Procter & Gamble Pharmaceuticals, Cincinnati, Ohio | 35-mg and 500-mg calcium tablets | Yes | 12 August 2005 |
| Zoledronic acid | Zometa | Novartis Pharmaceuticals, East Hanover, New Jersey | 4-mg vial† | Yes | 20 August 2001 |
| Ibandronate sodium | Boniva | Roche Laboratories Inc., Nutley, New Jersey | 2.5-mg tablet 150-mg tablet 3 mg/3 mL† | Yes | 16 May 2003 24 March 2005 6 January 2006 |

* This table shows the most common brand names. Generic forms, other names, and other doses may be available outside the United States. Clodronate is included because of its common use in Canada and Europe. FDA = Food and Drug Administration.
† Drug is administered intravenously.

Table 2. Reports of Cases of Bisphosphonate-Associated Osteonecrosis of the Jaws*

| Study, Year (Reference) | Patients, <i>n</i> | Sex, <i>n</i> | | Primary Diagnosis | Sites | Previous Surgical Procedure, <i>n</i> (%) | Medications |
|--|-----------------------|---------------|--------|---|---|--|--|
| | | Male | Female | | | | |
| Ruggiero et al., 2004 (25) | 63 | 18 | 45 | Myeloma (<i>n</i> = 29) Breast cancer (<i>n</i> = 21) Prostate cancer (<i>n</i> = 3) Lung cancer (<i>n</i> = 1) Uterine leiomyosarcoma (<i>n</i> = 1) Leukemia (<i>n</i> = 1) Osteoporosis (<i>n</i> = 7) | Mandible (<i>n</i> = 39) Maxilla (<i>n</i> = 23) Both (<i>n</i> = 1) | 54 (86) | Pamidronate (<i>n</i> = 34) Zoledronic acid (<i>n</i> = 9) Pamidronate and zoledronic acid (<i>n</i> = 13) Alendronate (<i>n</i> = 5) Risidronate (<i>n</i> = 1) Alendronate and zoledronic acid (<i>n</i> = 1) |
| Estilo et al., 2004 (26) | 13 | 4 | 9 | Breast cancer (<i>n</i> = 9) Myeloma (<i>n</i> = 4) | Mandible (<i>n</i> = 6) Maxilla (<i>n</i> = 5) Both (<i>n</i> = 2) | 9 (69) | Intravenous forms, not specified |
| Marx et al., 2005 (27) | 119 | NS | NS | Myeloma (<i>n</i> = 62) Breast cancer (<i>n</i> = 50) Prostate cancer (<i>n</i> = 4) Osteoporosis (<i>n</i> = 3) | Mandible (<i>n</i> = 81) Maxilla (<i>n</i> = 33) Both (<i>n</i> = 5) | 55 (46) | Zoledronic acid (<i>n</i> = 48) Pamidronate and zoledronic acid (<i>n</i> = 36) Pamidronate (<i>n</i> = 32) Alendronate (<i>n</i> = 3) |
| Migliorati et al., 2005 (28) | 18 | 4 | 14 | Breast cancer (<i>n</i> = 10) Myeloma (<i>n</i> = 3) Prostate cancer (<i>n</i> = 2) Ovarian cancer (<i>n</i> = 1) Ovarian/breast cancer (<i>n</i> = 1) Osteoporosis (<i>n</i> = 1) | Mandible (<i>n</i> = 8) Maxilla (<i>n</i> = 2) Both (<i>n</i> = 1) Unknown (<i>n</i> = 7) | 6 (33) | Zoledronic acid (<i>n</i> = 8) Pamidronate and zoledronic acid (<i>n</i> = 6) Pamidronate (<i>n</i> = 3) Alendronate (<i>n</i> = 1) |
| Purcell and Boyd, 2005 (29) | 13 | 7 | 6 | Breast cancer (<i>n</i> = 5) Prostate cancer (<i>n</i> = 4) Myeloma (<i>n</i> = 3) Osteoporosis (<i>n</i> = 1) | Mandible (<i>n</i> = 4) Maxilla (<i>n</i> = 2) Unknown (<i>n</i> = 7) | 5 (38) | Zoledronic acid (<i>n</i> = 9) Pamidronate (<i>n</i> = 2) Pamidronate and zoledronic acid (<i>n</i> = 1) Alendronate (<i>n</i> = 1) |
| Bagan et al., 2006 (30) | 20 | 5 | 15 | Breast cancer (<i>n</i> = 10) Myeloma (<i>n</i> = 9) Prostate cancer (<i>n</i> = 1) | Mandible (<i>n</i> = 11) Maxilla (<i>n</i> = 1) Both (<i>n</i> = 8) | 11 (55) | Zoledronic acid (<i>n</i> = 9) Pamidronate and zoledronic acid (<i>n</i> = 6) Pamidronate (<i>n</i> = 5) |
| Pires et al., 2005 (31) | 12 | 9 | 3 | Breast cancer (<i>n</i> = 6) Myeloma (<i>n</i> = 4) Prostate cancer (<i>n</i> = 1) Lung cancer (<i>n</i> = 1) | Mandible (<i>n</i> = 8) Maxilla (<i>n</i> = 3) Both (<i>n</i> = 1) | 8 (67) | Pamidronate and zoledronic acid (<i>n</i> = 5) Pamidronate (<i>n</i> = 4) Zoledronic acid (<i>n</i> = 3) |
| Bamias et al., 2006 (32) | 17 | 10 | 7 | Myeloma (<i>n</i> = 11) Prostate cancer (<i>n</i> = 3) Breast cancer (<i>n</i> = 2) Other neoplasm (<i>n</i> = 1) | Mandible (<i>n</i> = 14) Maxilla (<i>n</i> = 3) | 13 (76) | Pamidronate and zoledronic acid (<i>n</i> = 9) Zoledronic acid (<i>n</i> = 7) Zoledronic acid and ibandronate (<i>n</i> = 1) |
| Melo and Obeid, 2005 (33) | 11 | 7 | 4 | Breast cancer (<i>n</i> = 3) Myeloma (<i>n</i> = 7) Lung cancer (<i>n</i> = 1) | Mandible (<i>n</i> = 8) Maxilla (<i>n</i> = 2) Both (<i>n</i> = 1) | 9 (82) | Zoledronic acid (<i>n</i> = 4) Pamidronate (<i>n</i> = 4) Pamidronate and zoledronic acid (<i>n</i> = 3) |
| Zarychanski et al., 2006 (34) | 12 | 7 | 5 | Myeloma (<i>n</i> = 10) Breast cancer (<i>n</i> = 1) Renal cancer (<i>n</i> = 1) | Mandible (<i>n</i> = 10) Maxilla (<i>n</i> = 1) Both (<i>n</i> = 1) | 7 (58) | Pamidronate (<i>n</i> = 12) |
| Summary of studies with fewer than 10 patients (35–54)† | 70 | 38 | 23 | Myeloma (<i>n</i> = 29) Breast cancer (<i>n</i> = 26) Prostate cancer (<i>n</i> = 5) Paget disease (<i>n</i> = 3) Osteoporosis (<i>n</i> = 3) Lung cancer (<i>n</i> = 2) Lymphoma (<i>n</i> = 1) Mesothelioma (<i>n</i> = 1) | Mandible (<i>n</i> = 30) Maxilla (<i>n</i> = 14) Both (<i>n</i> = 9) Not assigned (<i>n</i> = 17) | 44 (63) | Zoledronic acid (<i>n</i> = 27) Pamidronate and zoledronic acid (<i>n</i> = 21) Pamidronate (<i>n</i> = 14) Alendronate (<i>n</i> = 5) Alendronate and zoledronic acid (<i>n</i> = 1) Pamidronate, zoledronic acid, and alendronate (<i>n</i> = 1) Oral ibandronate (<i>n</i> = 1) |

* NS = not stated.

† Sex was not reported for 9 patients in these studies.

were taking oral bisphosphonates for osteoporosis or Paget disease of bone (25, 27–29, 40, 50, 51).

Clinically, intraoral lesions appear as areas of exposed yellow-white, hard bone with smooth or ragged borders (Figures 1 and 2). Extraoral or intraoral sinus tracts may be

present (Figure 3). Painful ulcers may develop in soft tissues that impinge on the ragged bony margins.

Results of radiographic evaluation may be negative in early cases. Although some investigators have noted subtle changes, such as widening of the periodontal ligament,

Table 3. Primary Diagnoses and Types of Bisphosphonates in Reported Cases of Osteonecrosis of the Jaws

| Variable | Patients, n (%)* |
|---|------------------|
| Primary diagnosis | |
| Multiple myeloma | 171 (46.5) |
| Metastatic breast cancer | 143 (38.8) |
| Metastatic prostate cancer | 23 (6.2) |
| Osteoporosis | 15 (4.1) |
| Other metastatic disease† | 13 (3.5) |
| Paget disease of bone | 3 (0.8) |
| Total | 368 (100) |
| Bisphosphonate medications | |
| Zoledronic acid | 124 (35) |
| Pamidronate | 110 (31) |
| Pamidronate and zoledronic acid | 100 (28) |
| Oral alendronate | 15 (4.2) |
| Alendronate and zoledronic acid | 2 (0.6) |
| Oral risedronate | 1 (0.3) |
| Oral ibandronate | 1 (0.3) |
| Ibandronate and zoledronic acid | 1 (0.3) |
| Pamidronate, zoledronic acid, and alendronate | 1 (0.3) |
| Total | 355 (100) |
| Intravenous bisphosphonates, not specified | 13 |
| Patients with osteoporosis | |
| Receiving alendronate | 13 (87)‡ |
| Receiving risedronate | 1 (7)§ |
| Receiving alendronate and zoledronic acid | 1 (7)§ |

* Percentages may not sum to 100% because of rounding.
 † Five patients had lung tumors. Other diseases were leiomyosarcoma, leukemia, ovarian/breast cancer, ovarian cancer, renal cancer, lymphoma, mesothelioma, and "other."
 ‡ Nine of 11 cases were in the mandible, and 2 of 11 cases were in the maxilla. The remaining 2 cases were not specified.
 § All cases were in the mandible.

these findings are indistinguishable from chronic periodontal infection, a predisposing factor for osteonecrosis (27). Advanced cases show a moth-eaten, poorly defined radiolucency, with or without radio-opaque sequestra. In 1 series, 5 of 63 patients developed pathologic jaw fractures (25). Cultures of exposed bone may identify *Actinomyces* species, but care must be taken to distinguish between a true suppurative infection and mere surface colonization by *Actinomyces*, because such organisms are a common component of dental plaque.

Patients with bisphosphonate-associated osteonecrosis may present similarly to those with osteoradionecrosis of the jaws. Osteoradionecrosis is a complication of radiotherapy. It is thought to result from osteocyte and microvascular damage after the jaws are exposed to ionizing radiation and also frequently occurs after tooth extraction (56). Osteoradionecrosis, however, infrequently involves the maxilla (<5% of cases) and is more common in men than in women (57, 58).

RISK FACTORS AND ETIOPATHOGENESIS

The most important predisposing factors for the development of bisphosphonate-associated osteonecrosis of

the jaws are the type and total dose of bisphosphonate and history of trauma, dental surgery, or dental infection. Ninety-four percent of patients with osteonecrosis received pamidronate or zoledronic acid. The doses for oncologic indications are often up to 12 times higher than those used for osteoporosis (13, 59). Of interest, clodronate, a non-aminobisphosphonate, has not been implicated in the development of osteonecrosis (60). The risk for osteonecrosis of the jaws is substantially higher for patients taking zoledronic acid and increases over time, probably because of the long half-life of these drugs. Although oral lesions may develop after as few as 4 months of bisphosphonate therapy, the median duration of drug use ranged from 22 to 39 months (32, 38, 48) and the mean ranged from 9 to 14 months (27, 33). The cumulative hazard was 1% within the first year and 21% at 3 years of treatment with zoledronic acid. In contrast, it was 0% in the first year and 4% in the third year for patients receiving pamidronate alone or with subsequent zoledronic acid (32). Another study showed that 10% of 211 patients receiving zoledronic acid developed osteonecrosis compared with 4% of 413 patients receiving pamidronate (61).

A few cases have been reported in patients taking alendronate (10 mg/d) for osteoporosis (25, 27–29, 50, 51). One patient had taken alendronate for only 2 years (27). The concern is that with more women aging and taking bisphosphonates for longer periods of time, more cases of osteonecrosis may develop even in patients receiving alendronate or ibandronate therapy.

Trauma to oral tori is also associated with osteonecrosis (27) (Figure 2). Furthermore, 60% of patients had some form of dentoalveolar surgery resulting in nonhealing of the surgical site and necrosis of bone. Because most dentoalveolar surgeries are performed to treat dental infection, the contribution of each to the development of osteo-

Figure 1. Osteonecrosis of the right mandible after tooth extraction in a patient taking zoledronic acid for metastatic breast cancer.



Figure 2. Osteonecrosis of the palatal torus in a patient with osteoporosis taking alendronate.



necrosis is unclear, although it is likely that together they compound the problem.

Patients with myeloma tend to be prothrombotic and are often treated with other antiangiogenic agents, such as glucocorticoids, thalidomide, and the new proteasome inhibitors, such as bortezomib, in addition to bisphosphonates (62, 63). Although neither corticosteroids nor thalidomide has been shown to be associated with additional risk for osteonecrosis of the jaws, prospective studies are needed to more fully address this issue (32, 61). The impact of local factors, such as smoking, and of underlying medical conditions, such as diabetes or peripheral vascular diseases, remains to be determined.

SUSCEPTIBILITY OF THE JAWS TO OSTEONECROSIS

The question often asked is “Why the jaws?” First, the jaw bones are separated from a trauma-intense and microbiologically diverse oral environment by thin mucosa and periosteum. The fragility of this barrier is reflected by the condition known as *lingual mandibular sequestration*, which occurs in healthy adults yet resembles mild cases of bisphosphonate-associated osteonecrosis of the jaws (64). In this condition, 1- to 3-mm slivers of bone are sequestered in the area of the protuberant mylohyoid ridge with spontaneous resolution. It is thought that minor trauma causes local damage to the thin mucosa and underlying periosteum, leading to bone necrosis. Because the posterior lingual mandible is also a frequent site for osteonecrosis, it seems probable that the hypodynamic bone in patients receiving bisphosphonate therapy may turn this typically innocuous process into chronic bone exposure. Trauma to the periosteum may also serve to initiate osteonecrosis in patients wearing dentures or dental prostheses or in patients with prominent exostoses.

Second, teeth are readily infected by bacteria that cause caries and periodontal disease, 2 common infectious

diseases. Because the teeth are separated from bone by no more than 2 mm of periodontal connective tissue, such infections have easy access to the underlying bone. A case of osteonecrosis in the ear of a patient taking zoledronic acid for multiple myeloma was reported recently (44). The lesion occurred after removal of exostoses in the external auditory canal, and the patient had concurrent osteonecrosis of the maxilla.

We suggest that bisphosphonate-associated osteonecrosis of the jaws results from marked suppression of bone metabolism that results in accumulation of physiologic microdamage in the jawbones, compromising biomechanical properties. Trauma and infection increase demand for osseous repair that exceeds the capacity of the hypodynamic bone, resulting in localized bone necrosis. The antiangiogenic property of bisphosphonates and other medications and the presence of other comorbid factors may promote the risk for or persistence and progression of this condition.

PREVALENCE OF BIPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAWS

A Web-based survey conducted by the International Myeloma Foundation resulted in 1203 respondents, 904 with myeloma and 299 with breast cancer. Seven percent and 4% of patients with myeloma and breast cancer, respectively, reported osteonecrosis, and 6% and 8% of patients with myeloma and breast cancer, respectively, reported lesions suspicious for osteonecrosis (61). In a single-center study of 252 patients who had received intravenous bisphosphonates since January 1997, 10% of 111 patients with myeloma and 3% of 46 patients with breast cancer developed osteonecrosis (32). In another study of 124 patients with myeloma or breast cancer who were treated with intravenous bisphosphonates in a dental clinic in a cancer center, 4 and 9 patients with myeloma and breast

Figure 3. Extraoral fistula in a patient with intraoral osteonecrosis.



Key Summary Points

Osteonecrosis of the jaws is strongly associated with the use of aminobisphosphonates, and the mechanism of disease is probably severe suppression of bone turnover.

Ninety-four percent of patients are treated with zoledronic acid or pamidronate or both; 85% of affected patients have multiple myeloma or metastatic breast cancer, and 4% have osteoporosis.

The prevalence of osteonecrosis in patients with cancer is 6% to 10% and the prevalence in those taking alendronate for osteoporosis is unknown; osteonecrosis seems to be time- and dose-dependent because of the long half-life of aminobisphosphonates.

More than half of all cases (60%) occur after dentoalveolar surgery (such as tooth extraction) to treat infections, and the remaining 40% are probably related to infection, denture trauma, or other physical trauma.

Preventive strategies include removing all foci of dental infection before starting bisphosphonate therapy.

Treatment is directed toward control of pain and infection and careful local débridement of dead bone, but not wide excision of lesions.

cancer, respectively, developed osteonecrosis (prevalence of 10%) (26).

MANAGEMENT RECOMMENDATIONS

Treatment protocols have been outlined, but trials and outcomes of treatment and long-term follow-up data are not yet available (25, 27, 28, 65). In June 2004, an expert panel outlined recommendations for the management of bisphosphonate-associated osteonecrosis of the jaws (66). Because there are no randomized clinical trials that assess management strategies, we propose the following guidelines based on published literature, our own experience, and the experience of our colleagues.

We group patients who are either receiving bisphosphonate therapy or about to begin therapy into the following 3 broad categories: group 1, patients about to begin aminobisphosphonate therapy; group 2, patients without osteonecrosis of the jaws who are receiving aminobisphosphonate therapy; and group 3, patients with osteonecrosis of the jaws. Patients with osteoporosis who are taking oral preparations, such as alendronate, and are at lower risk than those receiving intravenous preparations are included in group 1. We note that the risks associated with oral ibandronate, recently approved for the treatment of osteoporosis, are unknown.

Patient management before initiation of therapy with aminobisphosphonates is targeted at eliminating active sites of infections to minimize future infections and the need for future dentoalveolar surgery, such as tooth extractions, to treat such infections. Similar protocols have been established for patients preparing for allogeneic stem-cell transplantation and those about to receive radiation to the head and neck (67, 68).

Recommendations for group 1, patients about to begin intravenous bisphosphonate therapy, are outlined in Table 4. It is probably not necessary to delay initiation of bisphosphonate therapy if dental treatment can be completed within 1 to 2 months. With drug use between 3 and 6 months, patients in group 2 (those receiving intravenous aminobisphosphonates who do not have signs of osteonecrosis of the jaws) should be evaluated on a case-by-case basis. Those who have been receiving intravenous bisphosphonate therapy for oncologic indications for more than 6 months are at risk for this condition. In group 3, patients with osteonecrosis of the jaws, there are anecdotal reports of the use of acrylic stents (with or without soft liners) to cover areas of exposed bone, protect adjacent soft tissues, and improve comfort. However, there is a risk that the stent may act as a fomite and that additional trauma may be caused by the stent itself.

Reduction of pain and regression or even resolution of lesions of osteonecrosis have been observed in patients treated with antibiotics and mouth rinses, withdrawal of bisphosphonates, and removal of loose sequestra (31, 45, 48). Extensive resection has not consistently resulted in wound closure and may lead to worsening or progression of disease (25, 27). However, even for patients with multiple myeloma who are potential candidates for hematopoietic stem-cell transplantation or continued chemotherapy, asymptomatic osteonecrosis may not necessarily pose a substantial risk for increased morbidity if there is no evidence of active infection, as characterized clinically by pain and suppuration. Hyperbaric oxygen therapy, given to a few patients, has only infrequently shown clinical efficacy (25, 27, 28, 32, 33, 36, 69).

DISCONTINUATION OF BISPHOSPHONATE THERAPY

Currently, there is no published evidence to support or oppose discontinuation of bisphosphonate therapy once osteonecrosis develops or before required dental surgery. Because of the long half-life of bisphosphonates, recovery of normal osteoclast function and bone turnover after drug withdrawal may be too gradual for this measure to have clinical significance. It is also unclear what effect, if any, discontinuation of such therapy would have on overall morbidity and mortality among patients with cancer.

Nevertheless, patients may benefit from bisphosphonate withdrawal. There have been anecdotal reports of healing and complete resolution of existing sites of osteonecrosis after several months of therapy cessation. The re-

Table 4. Management Recommendations*

| Patient Category | Treatment Recommendations |
|---|--|
| Group 1: patients about to begin aminobisphosphonate therapy | Treat active oral infections, eliminate sites at high risk for infection (partially impacted wisdom teeth, nonrestorable teeth, or teeth with substantial periodontal bone loss) Encourage routine dental care Perform biannual oral examination and dental cleaning Minimize periodontal inflammation Provide routine restorative care of carious teeth Provide endodontic therapy of nonsalvageable teeth |
| Group 2: patients without osteonecrosis of the jaws who are receiving intravenous aminobisphosphonate therapy | Less than 3 months of drug therapy Same as above for group 1 More than 3 months of drug therapy Seek conservative alternatives to surgical procedures (endodontic therapy with or without decoronation, scaling, and débridement) with appropriate local and systemic antibiotics Perform extractions and other surgery using minimal bone manipulation with appropriate local and systemic antibiotics; follow up to ensure healing |
| Group 3: patients with osteonecrosis of the jaws | Same as above for group 2 with more than 3 months of drug therapy Consider additional imaging studies, such as computed tomography scans Perform conservative removal of dead bone as necessary with minimal trauma to adjacent hard and soft tissues Prescribe oral rinses (0.12% chlorhexidine rinse, hydrogen peroxide) Prescribe systemic antibiotic therapy (monotherapy or combination therapy with β -lactam, tetracycline, macrolide, metronidazole, and/or clindamycin) Prescribe systemic analgesics as indicated Prescribe a soft acrylic stent Suggest discontinuation of bisphosphonate therapy until osteonecrosis heals or underlying disease progresses |

* Patients receiving or scheduled to begin bisphosphonate therapy should receive a comprehensive dental examination and panoramic and intraoral radiographs. Patients should be made aware of osteonecrosis, including its signs, symptoms, and sequelae.

removal of the antiangiogenic effects of the drug on the soft tissues and periosteum may play a role in healing. For this reason, discontinuation of oral bisphosphonate therapy for several weeks before and after dentoalveolar surgery may be warranted. Until data from clinical trials are available, the optimal timing and duration of such a drug holiday are somewhat arbitrary and must be weighed against the risks posed by not taking medication. If the patient's underlying systemic disease is stable, bisphosphonates can be withdrawn until the area of osteonecrosis heals or until clinical variables indicate disease progression.

RESEARCH AVENUES

Clinical trials are urgently needed to address many issues. Can alternative dosing schedules reduce the incidence of osteonecrosis while maintaining the enormous benefits of these drugs? For example, once the patient's condition is stabilized, perhaps lower-potency, nonaminobisphosphonates can be substituted in a maintenance role (60, 70). Monitoring bone turnover markers may help clinicians avoid oversuppression (71). A staging system can be developed, possibly including serologic and imaging data, that more accurately determines disease severity; this could then be used to guide treatment. Establishing criteria for the diagnosis of early changes that precede or predict bone exposures would also be desirable.

Prospective studies are also needed to more precisely

determine what additional risk factors, if any, may predispose the patient to the development of osteonecrosis of the jaws. Such variables as age, sex, medications, preexisting medical conditions, and individual genetic variations need to be examined. Finally, clinical trials should be done to determine the most effective treatment protocols for patients with this condition.

CONCLUSION

Osteonecrosis of the jaws is a newly recognized condition reported in patients treated with bisphosphonates, in particular potent aminobisphosphonates. Most cases have developed in patients with multiple myeloma or metastatic cancer, but the condition has also been identified in patients with osteoporosis. This article reviews the findings in 368 cases, suggests treatment strategies, and outlines research avenues that may help us better understand and treat this condition.

Note added in proof: An article describing this condition in 22 patients was recently published in the *Journal of Clinical Oncology*: Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. *J Clin Oncol.* 2006;24:945-52. [PMID: 16484704].

From Brigham and Women's Hospital and Harvard School of Dental Medicine, Boston, Massachusetts; University of Iowa College of Dentistry, Iowa City, Iowa; and The Ohio State University College of Dentistry, Columbus, Ohio.

Note: This is a position paper of the American Academy of Oral and Maxillofacial Pathology.

Grant Support: None.

Potential Financial Conflicts of Interest: *Grants received:* S.-B. Woo (Novartis).

Requests for Single Reprints: Sook-Bin Woo, DMD, Brigham and Women's Hospital, 45 Francis Street, Boston, MA 02115.

Current author addresses are available at www.annals.org.

References

1. Fleisch H. Bisphosphonates: mechanisms of action. *Endocr Rev.* 1998;19:80-100. [PMID: 9494781]
2. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. *Osteoporos Int.* 1999;9 Suppl 2:S66-80. [PMID: 10525729]
3. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. *Int J Clin Pract Suppl.* 1999;101:18-26. [PMID: 12669737]
4. Green JR. Bisphosphonates: preclinical review. *Oncologist.* 2004;9 Suppl 4:3-13. [PMID: 12584689]
5. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. *J Clin Invest.* 1989;83:1930-5. [PMID: 2524504]
6. Vitté C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. *Endocrinology.* 1996;137:2324-33. [PMID: 8641182]
7. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. *Ann Oncol.* 2003;14:1468-76. [PMID: 14504045]
8. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. *J Pharmacol Exp Ther.* 2002;302:1055-61. [PMID: 12183663]
9. Vincenzi B, Santini D, Dicuozzo G, Battistoni F, Gavasci M, La Cesa A, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. *J Interferon Cytokine Res.* 2005;25:144-51. [PMID: 15767788]
10. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. *Blood.* 2000;96:384-92. [PMID: 10887096]
11. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. *Leukemia.* 2005;19:664-70. [PMID: 15744346]
12. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. *Cancer.* 2000;88:1082-90. [PMID: 10699899]
13. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. *Cancer.* 2001;91:1191-200. [PMID: 11283917]
14. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. *Clin Prostate Cancer.* 2005;4:31-7. [PMID: 15992459]
15. Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. *J Bone Miner Metab.* 2005;23 Suppl:36-42. [PMID: 15984412]

16. Weinstein RS. True strength. *J Bone Miner Res.* 2000;15:621-5. [PMID: 10780853]
17. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. *N Engl J Med.* 2003;349:457-63. [PMID: 12890844]
18. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. *J Clin Endocrinol Metab.* 2005;90:1294-301. [PMID: 15598694]
19. Ott SM. Fractures after long-term alendronate therapy [Letter]. *J Clin Endocrinol Metab.* 2001;86:1835-6. [PMID: 11297626]
20. Ott SM. Long-term safety of bisphosphonates. *J Clin Endocrinol Metab.* 2005;90:1897-9. [PMID: 15758064]
21. Goodship AE, Walker PC, McNally D, Chambers T, Green JR. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. *Ann Oncol.* 1994;5 Suppl 7:S53-5. [PMID: 7873463]
22. Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, et al. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. *J Bone Miner Res.* 2001;16:429-36. [PMID: 11277259]
23. Gonzalez-Moles MA, Bagan-Sebastian JV. Alendronate-related oral mucosa ulcerations. *J Oral Pathol Med.* 2000;29:514-8. [PMID: 11048968]
24. Demerjian N, Bolla G, Spreux A. Severe oral ulcerations induced by alendronate. *Clin Rheumatol.* 1999;18:349-50. [PMID: 10468180]
25. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg.* 2004;62:527-34. [PMID: 15122554]
26. Estilo CS, Van Poznak CH, Williams T, Evtimovska E, Tkach L, Halpern JL, et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study [Abstract]. *Proc Am Soc Clin Oncol.* 2004;22:750.
27. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. *J Oral Maxillofac Surg.* 2005;63:1567-75. [PMID: 16243172]
28. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. *Cancer.* 2005;104:83-93. [PMID: 15929121]
29. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. *Med J Aust.* 2005;182:417-8. [PMID: 15850440]
30. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases [Letter]. *Oral Oncol.* 2006;42:327-9. [PMID: 16275156]
31. Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. *Oral Dis.* 2005;11:365-9. [PMID: 16269027]
32. Bamias A, Kastritis E, Bamia C, Mouloupoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. *J Clin Oncol.* 2005;23:8580-7. [PMID: 16314620]
33. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. *J Am Dent Assoc.* 2005;136:1675-81. [PMID: 16383049]
34. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. *Am J Hematol.* 2006;81:73-5. [PMID: 16369966]
35. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. *J Oral Maxillofac Surg.* 2003;61:1104-7. [PMID: 12966490]
36. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity [Letter]. *Am J Med.* 2004;117:440-1. [PMID: 15380503]
37. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. *Br J Haematol.* 2005;128:738. [PMID: 15755276]
38. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates [Letter]. *N Engl J Med.* 2005;353:99-102. [PMID: 16003838]
39. Viale PH, Lin A. Exposed bone in oral cavities. *Clin J Oncol Nurs.* 2005;9:355-7. [PMID: 15973847]
40. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. *Med J Aust.* 2005;182:413-5. [PMID: 15850439]

41. **Philipone E.** Nonhealing extraction site. *Gen Dent.* 2005;53:161, 163. [PMID: 15833019]
42. **Thronsdon RR, Healy SM, Zwickey MR.** Bisphosphonate-induced osteonecrosis of the jaws. *Tex Dent J.* 2005;122:960-5. [PMID: 16320503]
43. **Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A.** Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. *J Am Dent Assoc.* 2005;136:1669-74. [PMID: 16383048]
44. **Polizzotto MN, Cousins V, Schwarer AP.** Bisphosphonate-associated osteonecrosis of the auditory canal [Letter]. *Br J Haematol.* 2006;132:114. [PMID: 16371027]
45. **Sarathy AP, Bourgeois SL Jr, Goodell GG.** Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. *J Endod.* 2005;31:759-63. [PMID: 16186759]
46. **Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P.** Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. *J Oral Pathol Med.* 2005;34:613-7. [PMID: 16202082]
47. **Katz H.** Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. *J Endod.* 2005;31:831-4. [PMID: 16249730]
48. **Gibbs SD, O'Grady J, Seymour JF, Prince HM.** Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention [Letter]. *Med J Aust.* 2005;183:549-50. [PMID: 16296983]
49. **Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK.** Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? *J Craniomaxillofac Surg.* 2005;33:395-403. [PMID: 16253510]
50. **Yeo AC, Lye KW, Poon CY.** Bisphosphonate-related osteonecrosis of the jaws. *Singapore Dent J.* 2005;27:36-40. [PMID: 16438267]
51. **Marunick M, Miller R, Gordon S.** Adverse oral sequelae to bisphosphonate administration. *J Mich Dent Assoc.* 2005;87:44-9. [PMID: 16372548]
52. **Sitters MA, Caldwell CS.** Bisphosphonates, dental care and osteonecrosis of the jaws. *Tex Dent J.* 2005;122:968-72. [PMID: 16320504]
53. **Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al.** Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. *J Clin Periodontol.* 2005;32:1123-8. [PMID: 16212571]
54. **Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Pérez A, Sebastián-López C.** Osteonecrosis of the jaws and bisphosphonates. Report of three cases. *Med Oral Patol Oral Cir Bucal.* 2006;11:E76-9. [PMID: 16388300]
55. **Starck WJ, Epker BN.** Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. *Int J Oral Maxillofac Implants.* 1995;10:74-8. [PMID: 7615320]
56. **Marx RE.** Osteoradionecrosis: a new concept of its pathophysiology. *J Oral Maxillofac Surg.* 1983;41:283-8. [PMID: 6572704]
57. **Thorn JJ, Hansen HS, Specht L, Bastholt L.** Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. *J Oral Maxillofac Surg.* 2000;58:1088-93; discussion 1093-5. [PMID: 11021701]
58. **Reuther T, Schuster T, Mende U, Kübler A.** Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients—a report of a thirty year retrospective review. *Int J Oral Maxillofac Surg.* 2003;32:289-95. [PMID: 12767877]
59. **Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al.** Intravenous zoledronic acid in postmenopausal women with low bone mineral density. *N Engl J Med.* 2002;346:653-61. [PMID: 11870242]
60. **Jones JR, Lehtinen T, Riphagen FE, von Roemeling R.** Adverse event (AE) reporting of oral clodronate with emphasis on osteonecrosis of the jaws [Abstract]. Presented at the Annual Meeting of the American Society for Clinical Oncology, 2005. Abstract 799.
61. **Durie BG, Katz M, Crowley J.** Osteonecrosis of the jaw and bisphosphonates [Letter]. *N Engl J Med.* 2005;353:99-102. [PMID: 16000365]
62. **Drexler HC, Risau W, Konerding MA.** Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. *FASEB J.* 2000;14:65-77. [PMID: 10627281]
63. **Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, et al.** Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. *J Clin Oncol.* 2002;20:4319-23. [PMID: 12409330]
64. **Peters E, Lovas GL, Wysocki GP.** Lingual mandibular sequestration and ulceration. *Oral Surg Oral Med Oral Pathol.* 1993;75:739-43. [PMID: 8515988]
65. **Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al.** Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaws in patients with cancer. *Journal of Oncology Practice.* 2006;2:7-14.
66. **Expert Panel Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws: June 2004.** Professional Education Material. East Hanover, NJ: Novartis; 2004.
67. **Woo SB, Matin K.** Off-site dental evaluation program for prospective bone marrow transplant recipients. *J Am Dent Assoc.* 1997;128:189-93. [PMID: 9037972]
68. **Bishay N, Petrikowski CG, Maxymiw WG, Lee L, Wood RE.** Optimum dental radiography in bone marrow transplant patients. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1999;87:375-9. [PMID: 10102604]
69. **Carter GD, Goss AN.** Bisphosphonates and avascular necrosis of the jaws [Letter]. *Aust Dent J.* 2003;48:268. [PMID: 14738134]
70. **McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT.** Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. *Br J Haematol.* 2001;113:1035-43. [PMID: 11442499]
71. **Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, et al.** Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. *Anticancer Res.* 2005;25:1457-63. [PMID: 15865105]

Current Author Addresses: Dr. Woo: Brigham and Women's Hospital, 45 Francis Street, Boston, MA 02115.
Dr. Hellstein: University of Iowa, 356 Dental Science South, Iowa City, IA 52246.

Dr. Kalmar: The Ohio State University, 305 West 12th Avenue, Columbus, OH 43210.